Trial The STEP-HFpEF Trial Conducted at 96 sites in 13 countries in Asia, Europe, North America, and South America Randomized 529 patients between March 2021 and March 2022
Mistake 4: stopping cold turkey at high doses Both medications produce physiological changes that your body adapts to over months
The only clinically relevant difference between treatments was the higher frequency of gastrointestinal related adverse events with IcoSema versus icodec or semaglutide alone, which can be mitigated by appropriate dosing recommendations for IcoSema, as discussed above
I recommend keeping a food diary to track your intake and ensure you are getting a balanced mix of nutrients
Preliminary data and mechanistic understanding both suggest positive results, but the medical community rightly demands completed trials before making definitive claims
SARS-CoV-2 in the pancreas and the impaired islet function in COVID-19 patients